Biomm (BIOM3) reported that in August 2026 it delivered approximately 2.1 million cartridges of Glargilin (insulin glargine) to the public market, generating net revenue of R$ 35,950,000. According to the company, the figures are preliminary operating results and may undergo minor changes after the external audit.
Compared with the same month in 2025, the monetary volume of Glargilin deliveries in August 2026 grew 173%. Biomm states that this performance is in line with the company’s overall growth in the first half of 2026 compared with the first half of 2025.
The company highlighted that since July 2026 Glargilin has been available in all Brazilian states, with a usage recommendation for patients up to 18 years old with type 1 diabetes and over 70 years old with type 1 and type 2 diabetes. According to the announcement, supply volumes should continue to increase as patients in broader age groups gain access to the drug.
In August 2026 there were no deliveries of Wosulin (human insulin), as was also the case in August 2025. The supply contract for human insulin related to the second year of the Productive Development Partnership (PDP) is still in the process of being signed with the partners.
